肝毒性生物标志物研究进展  

Research progress in biomarkers of liver toxicity

作　　者：侯衍豹 黄妍 马莉[1] 刘静[1] 申秀萍[1] 张宗鹏[1] HOU Yan-bao, HUANG Yan, MA Li, LIU Jing, SHEN Xiu-ping, ZHANG Zong-peng(Tianjin Institute of Pharmaceutical Research Drug Safety Assessment Co. Ltd., Tianjin Engineering Research Center of drug preclinical assessment technology, Tianjin 300301, Chin)

机构地区：[1]天津药物研究院新药评价有限公司天津市新药非临床评价技术工程中心,天津300301

出　　处：《药物评价研究》2017年第12期1804-1810,共7页Drug Evaluation Research

基　　金：国家科技重大新药创制项目(2015ZX09501004);天津市科技计划项目(16PTGCCX00090)

摘　　要：药物肝毒性是医药界关注的重要问题。及时准确地评价药物的肝毒性,寻找特异性强、灵敏度高的肝毒性生物标志物对新药研发及保证临床用药安全具有重要意义。针对传统的肝毒性生物标志物(包括谷氨酸氨基转移酶、天冬氨酸氨基转移酶、谷氨酸脱氢酶等),以及新发现的生物标志物(血清F蛋白、嘌呤核苷磷酸酶、激肽原对氧磷酶)进行综述,为药物肝毒性的研究及防治提供参考。Drug hepatotoxicity is an important concern in the medical profession. Timely and accurate evaluation of drug hepatotoxicity and specific and sensitive biomarkers of liver toxicity are important for the research and development of new drugs and the safety of clinical medication. In this paper, traditional hepatotoxic biomarkers（including glutamate aminotransferase, aspartateaminotransferase, glutamate dehydrogenase, etc.） as well as newly discovered biomarkers（serum F protein, purine nucleoside phosphate Enzymes, kinin paraoxonase） were reviewed for the study and prevention of drug hepatotoxicity.

关 键 词：肝毒性 生物标志物 谷氨酸氨基转移酶 天冬氨酸氨基转移酶 血清F蛋白 嘌呤核苷磷酸酶 

分 类 号：R994[医药卫生—毒理学]